Protocol Ledger

NCT04948697 · Phase II · COMPLETED

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

Interventional Phase II clinical trial protocol NCT04948697 sponsored by BeiGene in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-20 Enrollment: 94 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04948697
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)94 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04948697
Protocol FieldVerified Registry Value
NCT IdentifierNCT04948697
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment94 participants (ACTUAL)
Registered Start Date2021-08-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI